Comparison of the Safety and Immunogenicity of Lyophilized IMVAMUNE (1x10exp8 TCID50) Versus Liquid Formulation IMVAMUNE (1x108 TCID50) Administered by the Subcutaneous Route and a Lower Dose Liquid Formulation IMVAMUNE (2x10exp7 TCID50) Administered by the Intradermal Route in Healthy Vaccinia-Naive Individuals.

Trial Profile

Comparison of the Safety and Immunogenicity of Lyophilized IMVAMUNE (1x10exp8 TCID50) Versus Liquid Formulation IMVAMUNE (1x108 TCID50) Administered by the Subcutaneous Route and a Lower Dose Liquid Formulation IMVAMUNE (2x10exp7 TCID50) Administered by the Intradermal Route in Healthy Vaccinia-Naive Individuals.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jan 2015

At a glance

  • Drugs Smallpox vaccine (Primary) ; Smallpox vaccine (Primary)
  • Indications Smallpox
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 14 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 23 Sep 2010 Planned end date changed from 1 Jan 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top